Tenaya Therapeutics (TNYA) has unveiled initial results from the MyPEAK-1 clinical trial's first cohort of patients undergoing TN-201 gene therapy. This therapy is being developed as a potential treatment for MYBPC3-associated hypertrophic cardiomyopathy, a condition stemming from inadequate levels of myosin-binding protein C. The company noted that the TN-201 data align with its expectations for this early phase of the study.
Preliminary findings from three patients in the initial dose cohort of 3E13 vg/kg indicate that TN-201 is generally well tolerated. Tenaya plans to continue monitoring these patients, with further data from the first cohort and the higher dosage second cohort expected by 2025.
On Tuesday, shares of Tenaya Therapeutics have fallen by 26% in pre-market trading.
